Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Cardiff Oncology ( (CRDF) ) has provided an update.
On June 26, 2025, Cardiff Oncology, Inc. held its Annual Meeting of Stockholders where 38,649,891 shares of common stock were represented. During the meeting, all seven nominees for director were elected to serve until the 2026 Annual Meeting. Additionally, the stockholders ratified the appointment of BDO USA, P.C. as the independent registered public accounting firm, approved an amendment to the 2021 Equity Incentive Plan to increase the number of shares issuable, and endorsed the compensation of the company’s named executive officers.
The most recent analyst rating on (CRDF) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Cardiff Oncology stock, see the CRDF Stock Forecast page.
Spark’s Take on CRDF Stock
According to Spark, TipRanks’ AI Analyst, CRDF is a Neutral.
Cardiff Oncology’s stock score is primarily influenced by its significant financial challenges, which weigh heavily despite a strong balance sheet. Technical indicators provide mixed signals, and the lack of positive valuation metrics further impacts the score. However, recent corporate events, including leadership changes and upcoming trial data, offer potential positives.
To see Spark’s full report on CRDF stock, click here.
More about Cardiff Oncology
Average Trading Volume: 1,209,112
Technical Sentiment Signal: Sell
Current Market Cap: $206.2M
See more insights into CRDF stock on TipRanks’ Stock Analysis page.